Klivira
Request demo

Auvelity Prior Authorization for Cardiology: Streamlining Approval Workflows

Managing prior authorizations for high-volume drugs like Auvelity can significantly impact cardiology practices, particularly when treating patients with complex comorbidities.

Cardiology departments already navigate a high volume of prior authorizations for advanced cardiac imaging, interventional procedures, and specialty cardiovascular drugs. The additional administrative burden of processing PAs for non-cardiovascular medications, such as Auvelity for depression, further strains revenue cycle teams and can delay patient access to essential treatment.

The Intersection of Auvelity Prior Authorization and Cardiology Care

While Auvelity is indicated for Major Depressive Disorder, cardiology practices frequently manage patients with complex comorbidities. When Auvelity is prescribed for these patients by a referring provider or within a multidisciplinary care model, the cardiology practice's revenue cycle team may be responsible for managing the prior authorization process, adding to their existing workload.

Essential Documentation for Auvelity Prior Authorization

  • Confirmed diagnosis of Major Depressive Disorder (MDD)
  • Documented trial and failure of alternative antidepressant therapies (e.g., SSRIs)
  • Clinical rationale for Auvelity as the chosen treatment
  • Patient's current medication list and relevant medical history
  • Relevant psychiatric evaluation notes or consultation reports

Common Prior Authorization Hurdles for Auvelity in a Cardiology Setting

Cardiology practices encounter challenges such as payer-specific step therapy requirements and the critical need for detailed clinical notes justifying the prescription of Auvelity. Potential denials based on documentation gaps or insufficient evidence of prior therapy trials add to the administrative load, impacting timely patient access to medication within a department already managing high PA volumes for cardiac services.

Workflow Impact on Cardiology Revenue Cycle Teams

Managing Auvelity prior authorizations contributes to the extensive administrative burden on cardiology revenue cycle teams, alongside high-volume PAs for cardiac imaging, interventional procedures, and specialty cardiovascular drugs like PCSK9 inhibitors or sacubitril/valsartan. This fragmented and often manual process can strain resources, leading to delays in patient care and increased operational costs.

Klivira's Solution for Streamlined Drug Prior Authorization in Cardiology

Klivira's platform automates the entire prior authorization workflow for medications, including those like Auvelity, which may be prescribed for comorbidities in cardiac patients. By integrating with EMRs and payer portals, Klivira reduces manual effort, accelerates submission times, and improves the efficiency of prior authorization processing for cardiology revenue cycle teams.

Klivira's Capabilities for Comprehensive PA Management

  • Automated submission to payer portals and specialty benefit managers (e.g., Carelon MBM, eviCore successor vendors, NIA/Magellan)
  • Real-time status tracking and proactive alerts for PA requests
  • Intelligent policy logic to guide documentation for drug-specific criteria
  • Integration with EMR systems (e.g., SMART on FHIR) for seamless data exchange
  • Support for X12 278 and ePA standards for efficient communication

Frequently asked questions

Why would a cardiology practice need to manage Auvelity prior authorizations?

Cardiology patients often have significant comorbidities, including major depressive disorder. When Auvelity is prescribed for these patients by a referring provider or within a multidisciplinary care model, the cardiology practice's revenue cycle team may be responsible for managing the prior authorization process, ensuring coordinated patient care.

What specific documentation is typically required for Auvelity PA approval?

While specific requirements vary by payer, common documentation includes a confirmed diagnosis of Major Depressive Disorder, evidence of prior trials and failures of other antidepressant therapies, and the clinical rationale for choosing Auvelity. This aligns with general drug PA requirements and payer policies.

How does Klivira assist cardiology practices with drug prior authorizations like Auvelity?

Klivira automates the entire prior authorization workflow for medications, including Auvelity. Our platform integrates with EMRs and payer systems, streamlining documentation, submission, and status tracking. This reduces the administrative burden on cardiology revenue cycle teams, allowing them to focus on patient care.

Are there specific cardiology guidelines that reference Auvelity?

Auvelity is indicated for Major Depressive Disorder, not a primary cardiovascular condition. Therefore, it is not typically referenced in cardiology-specific guidelines such as those from the ACC/AHA. PA criteria will focus on psychiatric indications and prior treatment history, rather than cardiovascular pathways.

Does Klivira handle prior authorizations submitted via specialty benefit managers for drugs?

Yes, Klivira's platform is designed to identify and route prior authorization requests, including for specialty drugs, to the appropriate channels. This includes direct submission to payer portals or through prevalent specialty benefit-management vendors like Carelon MBM, eviCore successor vendors, or NIA/Magellan, as indicated by the payer.

Related coverage

Other auvelity prior authorization by payer

Other auvelity prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo